Skip to content
Buy This GLP
← Research
Evidence

Why Is Semaglutide Expensive? What a Generic Cost Model Found

Researchers modeled possible generic semaglutide prices using ingredient shipment data and assumptions about production and distribution.

Editorial profile: Carla MedinaBuy This GLP Editorial Team9 min read
Modeled generic costs per person-yearInjection$28–$140Tablet$186–$380

A 2026 study modeled potential launch prices for generic semaglutide using Indian ingredient shipment data from 2024 and 2025 [1]. Our guide to generic Ozempic availability covers the separate question of whether an approved generic can be purchased in the United States. The estimate used assumptions about manufacturing and distribution.

What went into the estimate?

The model estimated $28 to $140 per person-year for generic injections and $186 to $380 for tablets. Formulation, packaging, taxes and a profit assumption were included [1]. The estimated cost of disposable pens was 8-fold to 68-fold higher than the modeled ingredient and other production costs combined [1].

Why can a consumer’s price be higher?

The researchers identified patent and health-system barriers to generic access. A comparison of current GLP-1 costs uses published program terms and separates relevant billing charges. The model estimates a possible generic price under its assumptions. It cannot explain how much each factor adds to a particular bill.

Frequently asked

Is $28 to $140 an offer I can buy?
It is an estimated annual range for potential generic injections. The estimate depends on assumptions about ingredients, formulation, taxes and a profit margin.

Sources

  1. [1] Levi J, Cross S, Ramesh N, Venter F, Hill A (2026). How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access Obesity (Silver Spring, Md.). PMID 42437874

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence